Company Information
Industry 制造业
Company Introduction 公司是以酶制剂、微生态制剂的生产、研发和销售为主营业务的生物科技公司。公司以“生物科技还原生态世界”为宗旨,致力于为生物制造提供核心技术支持,为传统产业提供清洁节能技术,为食品安全提供绿色解决方案,全程服务农牧、纺织、食品等多个产业。 公司合作研发的“饲料用酶技术体系创新及重点产品创制”项目荣获国务院颁发的国家科技进步二等奖。 公司被国家发展改革委、财政部、海关总署、税务总局联合评为“国家认定企业技术中心”,在2015年全国1,098家国家认定企业技术中心评价中,公司在生物行业中排名第1位。 凭借公司在行业内的技术领先和主导地位,公司及其子公司共主持国际合作专项、国家863课题等国家级项目33项,参与20项,并主持、参与酶制剂、动物保健行业方面的国家和行业标准制定41项,其中39项已颁布,2项待颁布。 公司及其子公司还先后被评为“国家技术创新示范企业”、“国家动物用保健品工程技术研究中心”、“生物催化技术国际联合研究中心”、“高新技术企业”、“生物催化技术国家地方联合工程实验室”、“中国轻工业工业酶菌种选育重点实验室”、“农业部动物保健工程技术重点实验室”、“全国酶制剂行业十强企业”、“山东省引才工作重点支持企业”、“‘十二五’轻工业科技创新优秀集体”。
Main Business 从事酶制剂、微生态以及动物保健品的研发、生产和销售。
Legal Representative 陈刚
Top Executives
董事长:陈刚
名誉董事长:黄炳亮
董事:贾德强,陈刚,乔丕远
独立董事:王京,林英庭
Top 5 Shareholder
Shareholder name Nature Holding Date
青岛康地恩实业有限公司流通A股44.42%30/09/2024
西藏思壮投资咨询有限公司流通A股7.03%30/09/2024
西藏善诚投资咨询有限公司流通A股7.03%30/09/2024
贾德强流通A股3.74%30/09/2024
陈刚流通A股2.84%30/09/2024
Company Secretary 姜勇
Solicitors 北京海润天睿律师事务所
Auditors 致同会计师事务所(特殊普通合伙)
Tel No 0532-88978071
Fax No 0532-88966609
Website www.vlandgroup.com
Email vland@vlandgroup.com
Company Address
Register: 山东省青岛城阳区王沙路1318号企业服务中心108室
Office: 山东省青岛市崂山区九水东路596-1号
Listing Date 16/01/2019
Shares Capital
Shares Capital: 253,028,866
Total A Share: 253,028,866
Listed A Share: 253,028,866
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.320
DPS(RMB)* ¥ 0.100
NBV Per Share(RMB)* ¥ 6.751
Market Capitalization(RMB) 3.838B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.